featured
Tazemetostat in Advanced Epithelioid Sarcoma With Loss of INI1/SMARCB1
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tazemetostat in Advanced Epithelioid Sarcoma With Loss of INI1/SMARCB1: An International, Open-Label, Phase 2 Basket Study
Lancet Oncol 2020 Oct 06;[EPub Ahead of Print], M Gounder, P Schöffski, RL Jones, M Agulnik, GM Cote, VM Villalobos, S Attia, R Chugh, TW Chen, T Jahan, ET Loggers, A Gupta, A Italiano, GD Demetri, R Ratan, LE Davis, O Mir, P Dileo, BA Van Tine, JG Pressey, T Lingaraj, A Rajarethinam, L Sierra, S Agarwal, S StacchiottiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.